Provided by Tiger Trade Technology Pte. Ltd.

PolyPid Ltd.

5.04
-0.0600-1.18%
Volume:108.60K
Turnover:556.16K
Market Cap:102.37M
PE:-3.41
High:5.18
Open:5.12
Low:5.04
Close:5.10
52wk High:5.73
52wk Low:3.06
Shares:20.31M
Float Shares:12.16M
Volume Ratio:0.94
T/O Rate:0.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4762
EPS(LYR):-2.0900
ROE:-243.59%
ROA:-74.63%
PB:19.00
PE(LYR):-2.41

Loading ...

Polypid Partners with Azurity to Commercialize D-plex100 in US, Canada

Reuters
·
Jul 21

Polypid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-plex₁₀₀ in the U.S. and Canada

THOMSON REUTERS
·
Jul 21

Polypid - U.S. Launch of D-plex100 Targeted for Q1 2027

THOMSON REUTERS
·
Jul 21

Polypid - to Receive $15 Mln Upfront and $15 Mln on FDA Nda Acceptance

THOMSON REUTERS
·
Jul 21

Polypid - to Receive over $320 Mln in Payments Plus Tiered Royalties

THOMSON REUTERS
·
Jul 21

Polypid Says it Could Receive More than $320 Million in Upfront and Milestone Payments

THOMSON REUTERS
·
Jul 21

Israel's Polypid, Azurity Pharmaceuticals Sign Commercialisation Deal for D-plex100 Drug to Prevent Surgical Site Infections

THOMSON REUTERS
·
Jul 21

Polypid Sets 5,012,403-share Option Pool Under Amended 2012 Equity Plan

Reuters
·
Jul 16

Lilly’s $780M Bet is Reshaping Surgical Infection Prevention, and PolyPid’s Asset is Hiding in Plain Sight

TIPRANKS
·
Jun 26

PolyPid Sets July 15, 2026 Shareholder Meeting to Vote on Board, Auditor and Equity Grants

TIPRANKS
·
Jun 11

PolyPid announces shareholder meeting notice

Reuters
·
Jun 11

PolyPid submits D-PLEX100 NDA to FDA under rolling review

Reuters
·
Jun 01

PolyPid - FDA Decision on D-Plex100 Expected in Q1 2027 Under Pdufa Timeline

THOMSON REUTERS
·
Jun 01

PolyPid Completes New Drug Application Submission to FDA for D-Plex₁₀₀

THOMSON REUTERS
·
Jun 01

PolyPid management attends Craig-Hallum institutional investor conference investor meetings

Reuters
·
May 20

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

GlobeNewswire
·
May 20

PolyPid’s Earnings Call Signals Tightrope to Approval

TIPRANKS
·
May 20

PolyPid reports Q1 EPS (35c), consensus (43c)

TIPRANKS
·
May 14

PolyPid Ltd reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 13

PolyPid Advances D-PLEX₁₀₀ Toward FDA Review as Q1 2026 Loss Narrows and Debt Is Retired

TIPRANKS
·
May 13